RAAS抑制对长期连续流左心室辅助装置支持的发病与死亡影响:IMACS报告
基于IMACS登记,分析2013年1月至2017年9月植入初次连续流LVAD、术后3个月存活且无重大不良事件的成人患者,按ACEI/ARB或MRA治疗分组并行倾向评分匹配。ACEI/ARB与更低死亡独立相关,MRA未见生存获益。
要点
- ACEI/ARB治疗与LVAD后更低死亡独立相关(HR 0.81)。
- MRA治疗未显示生存获益(HR 1.03)。
- ACEI/ARB组心血管死亡与消化道出血风险更低。
核心结论
- 提示LVAD植入后心力衰竭患者可从ACEI/ARB治疗中获益。
研究设计与样本
- 分析ISHLT IMACS登记中2013年1月至2017年9月植入初次连续流LVAD的成人患者,纳入术后3个月存活且无重大不良事件者,并按ACEI/ARB或MRA治疗分组。
- ACEI/ARB与无治疗倾向评分匹配各n=4,118;MRA与无治疗倾向评分匹配各n=3,892。
主要发现
- 共纳入11,494例患者,50%接受ACEI/ARB,38%接受MRA。
- Kaplan-Meier生存ACEI/ARB组显著更优(p < 0.001),MRA组无显著差异(p = 0.31)。
- 校正LVAD后死亡已知预测因素后,ACEI/ARB与更低死亡独立相关(HR 0.81 [95%CI 0.71-0.93],p < 0.0001),MRA无独立关联(HR 1.03 [95%CI 0.88-1.21],p = 0.69)。
- ACEI/ARB组未校正心血管死亡风险(p < 0.001)、消化道出血风险(p = 0.01)及肌酐水平(p < 0.001)显著更低。
- MRA治疗与更低消化道出血风险(p = 0.01)相关,但与更高溶血风险(p < 0.01)相关。
临床怎么用
- 对LVAD植入后心力衰竭患者,可考虑ACEI/ARB治疗以改善生存并降低心血管死亡与消化道出血风险。
- MRA在LVAD后的生存获益未获支持,且需关注溶血风险。
局限性
- 存在残余混杂与治疗交叉。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inhibition of the renin angiotensin aldosterone system (RAAS) improves survival and reduces adverse cardiac events in heart failure with reduced ejection fraction, but the benefit is not well-defined following left ventricular assist device (LVAD). METHODS: We analyzed the ISHLT IMACS registry for adults with a primary, continuous-flow LVAD from January 2013 to September 2017 who were alive at postoperative month 3 without a major adverse event, and categorized patients according to treatment an angiotensin converting enzyme inhibitor (ACEI/ARB) or mineralocorticoid receptor antagonist (MRA). Propensity score matching was performed separately for ACEI/ARB vs none (n = 4,118 each) and MRA vs none (n = 3,892 each). RESULTS: Of 11,494 patients included, 50% were treated with ACEI/ARB and 38% with MRA. Kaplan-Meier survival was significantly better for patients receiving ACEI/ARB (p < 0.001) but not MRA (p = 0.31). In Cox proportional hazards analyses adjusted for known predictors of mortality following LVAD, ACEI/ARB use (hazard ratio 0.81 [95% confidence interval 0.71-0.93], p < 0.0001) but not MRA use (hazard ratio 1.03 [95% confidence interval 0.88-1.21], p = 0.69) was independently associated with lower mortality. Among patients treated with an ACEI/ARB, there was a significantly lower unadjusted risk of cardiovascular death (p < 0.001), risk of gastrointestinal bleeding (p = 0.01), and creatinine level (p < 0.001). MRA therapy was associated with lower risk of gastrointestinal bleeding (p = 0.01) but higher risk of hemolysis (p < 0.01). Potential limitations include residual confounding and therapy crossover. CONCLUSION: These findings suggest a benefit for ACEI/ARB therapy in patients with heart failure after LVAD implantation.
引用
- Brinkley DM, Wang L, Yu C, et al. Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: An IMACS report. J Heart Lung Transplant. 2021. PMID: 34663529. doi:10.1016/j.healun.2021.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。